T1	Participants 93 122	B-cell non-Hodgkin's lymphoma
T2	Participants 435 471	patients with non-Hodgkin's lymphoma
T3	Participants 473 577	Twenty seven patients were mobilized with etoposide and G-CSF and 28 with etoposide, G-CSF and rituximab
